OTCPK:PRTX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States.


Snowflake Analysis

Mediocre balance sheet with weak fundamentals.

Share Price & News

How has Protalex's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRTX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

PRTX

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

-94.6%

PRTX

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: PRTX underperformed the US Biotechs industry which returned 23.9% over the past year.

Return vs Market: PRTX underperformed the US Market which returned 8.9% over the past year.


Shareholder returns

PRTXIndustryMarket
7 Day0%-1.5%3.8%
30 Day28.6%3.5%11.4%
90 Day8.0%9.0%6.8%
1 Year-94.6%-94.6%23.3%22.1%12.1%9.7%
3 Year-99.7%-99.7%26.1%22.1%36.2%27.2%
5 Year-100.0%-100.0%-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is Protalex's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Protalex undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether Protalex is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Protalex has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of PRTX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Protalex regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Protalex forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

30.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Protalex has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Protalex performed over the past 5 years?

22.7%

Historical Pharmaceuticals & Biotech annual earnings growth


Earnings and Revenue History

Quality Earnings: Insufficient data to determine if PRTX has high quality earnings.

Growing Profit Margin: Insufficient data to determine if PRTX's profit margins have improved over the past year.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if PRTX's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Insufficient data to compare PRTX's past year earnings growth to its 5-year average.

Earnings vs Industry: Insufficient data to determine if PRTX's earnings growth over the past year exceeded the Biotechs industry average.


Return on Equity

High ROE: PRTX has a negative Return on Equity (0%), as it is currently unprofitable.


Next Steps

Financial Health

How is Protalex's financial position?


Financial Position Analysis

Short Term Liabilities: Insufficient data to determine if PRTX's short term assets cover its short term liabilities.

Long Term Liabilities: PRTX has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRTX is debt free.

Reducing Debt: PRTX currently has no debt however we can't compare to 5 years ago as we have no data for that period.

Debt Coverage: PRTX has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: PRTX has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Next Steps

Dividend

What is Protalex's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.3yrs

Average management tenure


CEO

Protalex has no CEO, or we have no data on them.


Leadership Team

NamePositionTenureCompensationOwnership
Arnold Kling
President & Director10.58yrsUS$274.50kno data
William Gannon
Chief Medical Officer & Member of Scientific Advisory Boardno datano datano data
John McClain
Medical Director & Member of Scientific Advisory Board6.08yrsno datano data
Michelle Catalina
Director of Preclinical Studies & Member of Scientific Advisory Board6.08yrsno datano data

8.3yrs

Average Tenure

Experienced Management: PRTX's management team is seasoned and experienced (8.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Arnold Kling
President & Director10.58yrsUS$274.50kno data
William Gannon
Chief Medical Officer & Member of Scientific Advisory Boardno datano datano data
John McClain
Medical Director & Member of Scientific Advisory Board6.08yrsno datano data
Michelle Catalina
Director of Preclinical Studies & Member of Scientific Advisory Board6.08yrsno datano data
Benjamin Bowen
Chairman of Scientific Advisory Boardno datano datano data
James Dowe
Vice Chairman of Scientific Advisory Board10.5yrsno datano data
Richard Francovitch
Member of Scientific Advisory Board6.08yrsno datano data

6.1yrs

Average Tenure

Experienced Board: PRTX's board of directors are considered experienced (6.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Protalex, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Protalex, Inc.
  • Ticker: PRTX
  • Exchange: OTCPK
  • Founded: 1999
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$127.778k
  • Shares outstanding: 47.33m
  • Website: https://www.protalex.com

Number of Employees


Location

  • Protalex, Inc.
  • 131 Columbia Turnpike
  • Suite 1
  • Florham Park
  • New Jersey
  • 7932
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRTXOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 1999

Biography

Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/05 12:00
End of Day Share Price2020/05/29 00:00
Earnings2018/08/31
Annual Earnings2018/05/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.